Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;45(2):195-201.
doi: 10.5114/ceji.2020.97909. Epub 2020 Jul 27.

Human(ized) monoclonal antibodies in atopic patients - state of the art

Arzu Didem Yalcin  1   2 , Kevser Onbasi  3 , Rusen Uzun  4 , Felix Herth  5 , Philipp Albert Schnabel  6
Affiliations
Review

Human(ized) monoclonal antibodies in atopic patients - state of the art

Arzu Didem Yalcin et al. Cent Eur J Immunol. 2020.

Abstract

Asthma is an important chronic disease affecting a lot of people worldwide. Treatment options for asthma like biological agents are being developed more frequently nowadays. Despite a lot of treatment options, some patients still remain symptomatic. As more and more practitioners choose treatment with biologic agents as a convenient way of therapy, biologic agents and other valuable methods must be discovered in order to cope with a growing number of treatment agents. This manuscript emphasizes on new generation monoclonal human(ized) antibodies in asthmatics and off-label use . The first developed biologic agent is the anti-immunoglobulin E monoclonal antibody called omalizumab. Currently it is an approved treatment option for asthma.

Keywords: anti IL-5; asthma; humanized monoclonal antibodies; omalizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Beasley R, Semprini A, Mitchell EA (2015): Risk factors for asthma: is prevention possible? Lancet 386: 1075-1085. - PubMed
    1. Yalcin AD, Celik B, Gumuslu S (2014): D-dimer levels decreased in severe allergic asthma and chronic urticaria patients with the omalizumab treatment Expert Opin Biol Ther 14: 283-286. - PubMed
    1. Yalcin AD. (2015): Advances in anti-IgE therapy. Biomed Res Int 2015: 317465. - PMC - PubMed
    1. Yalcin AD, Cilli A, Bisgin A, et al. (2013): Omalizumab is effective in treating severe asthma in patients with severe cardiovascular complications and its effects on sCD200, d-dimer, CXCL8, 25-hydroxyvitamin D and IL-1ß levels. Expert Opin Biol Ther 13: 1335-1341. - PubMed
    1. Mitchell PD, El-Gammal AI, O’Byrne PM (2016): Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma. Clin Pharmacol Ther 99: 38-48. - PubMed